A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Clinical trial NCT06982924 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06982924
Sponsor: Shanghai Chest Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer PD-L1 Positive

Start date: 2025-06-30
Primary completion: 2026-12-30
Enrollment: 136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.